HAMBURG, Germany and BASEL, Switzerland, June 24, 2011 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) and Roche (SIX:RO) (SIX:ROG) (OTCQX:RHHBY) today announced a collaboration in novel protein-activity based biomarkers for Roche's oncology drugs under development. Evotec AG will employ its PhosphoScout® platform to discover protein-phosphorylation's that predict favorable dosage and efficacy of targeted cancer drugs in patients. Roche will be responsible for conducting clinical trials as well as assessing the development of companion diagnostics for patient stratification.
